Company intelligence / Profile preview

PharmAla Biotech Holdings

Vancouver, British Columbia, Canada

Ownership: Private
Development stage: Other

Overview

PharmAla Biotech is primarily a supplier of clinical‑grade MDMA (LaNeo MDMA) and related MDXX molecules to clinical researchers globally and is conducting preclinical proof‑of‑concept work on several patented MDXX novel chemical entities (including ALA-002 and PharmAla-1); as of the latest disclosures, its proprietary drug candidates are in preclinical development with no completed human clinical trial results reported[3][5][7][8][10].

Therapeutic areas: Psychiatry
Modalities: Small molecule
Industry: Biotech

Partnerships

Exclusive GLP/GMP MDMA supply partnership with Awakn Life Sciences/Awakn LS Europe Holdings for MDMA R&D programs[2][6].Joint venture with Cortexa for MDMA and psilocybin supply and commercialization in Australia (via shipments and permanent JV structure)[5].

Beyond the preview

Go deeper on PharmAla Biotech Holdings.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PharmAla Biotech Holdings.

Explore the full profile